Clinical trials
Phase 4 Respiratory Tract Infections trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
63 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 3 |
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 5 |
| 2011 | 5 |
| 2013 | 5 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 40 |
| Recruiting | 8 |
| Terminated | 5 |
| Unknown status | 5 |
| Not yet recruiting | 2 |
| Withdrawn | 1 |
| Suspended | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sanofi | 3 |
| Xiangbei Welman Pharmaceutical Co., Ltd | 3 |
| A. Vogel AG | 1 |
| Ain Shams University | 1 |
| Almirall, S.A. | 1 |
| Bayer | 1 |
| Beth Israel Deaconess Medical Center | 1 |
| BioHealth Technologies Inc. | 1 |
| BioNTech SE | 1 |
| Campus Bio-Medico University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Respiratory Tract Infections | 63 |
| Influenza, Human | 10 |
| COVID-19 | 6 |
| Common Cold | 6 |
| Pneumonia | 6 |
| Cough | 5 |
| Fever | 4 |
| Infections | 4 |
| Orthomyxoviridae Infections | 4 |
| Asthma | 3 |
Trials
Showing 51 to 63 of 63. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.